UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) --  Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 3:45 p.m. ET. The webcast of the presentation wil ...

Osteoporosis Program: Phase 2 analysis exploring the dual actions of oral PTH(1-34) tablet treatment, EB613 on trabecular and cortical bone, and Next-Gen EB613 PK/PD data slated for oral and poster presentations at ASBMRShort Bowel Syndome and Rare GI Disorders: PK/PD of oral GLP-2 tablet candidate poster presentation at ESPENCorporate Overview at H.C. Wainwright Investor Conference JERUSALEM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and ...

STOCKHOLM, SWEDEN August 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has raised SEK 28.3 million in a unit issue with a subscription rate of 189 percent. The proceeds from the rights issue are intended to finance the continued development of the drug candidate, sevuparin, for the treatment of chronic kidney disease. Modus Therapeutics, listed on Nasdaq First North Growth Market, has successfully carried out a unit issue, provid ...

CELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced four posters on MIPLYFFA® (MY-PLY-FAH) (arimoclomol) will be presented at the International Congress of Inborn Errors of Metabolism (ICIEM), taking place September 2-6, 2025, in Kyoto, Japan. MIPLYFFA is approved in the U.S. for the treatment of Niemann-Pick disease type C (NPC). ...

Core Insights - Veeva Systems has announced a collaboration with Amgen to enhance clinical trial innovation, utilizing the Veeva Clinical Platform to improve efficiencies in the clinical trial process [1][2][3] Group 1: Collaboration Details - Amgen aims to leverage advanced technology through this collaboration to enhance its end-to-end trial operations, which is expected to expedite the delivery of innovative treatments to patients [2] - The Veeva Clinical Platform will serve as the backbone for standardized and connected processes, facilitating faster delivery of life-saving drugs [3] Group 2: Veeva Clinical Platform Overview - The Veeva Clinical Platform is a comprehensive and connected solution that encompasses various clinical operations and data applications, including CTMS, EDC, clinical workbench, RTSM, eCOA, eTMF, and more [4] - This platform is designed to streamline clinical trials from initiation to completion, automating data flow and enhancing operational efficiency [4] Group 3: Company Background - Veeva Systems provides industry-specific cloud solutions for life sciences, serving over 1,500 customers, including major biopharmaceutical companies and emerging biotech firms [5] - The company is committed to innovation, product excellence, and balancing the interests of all stakeholders, including customers, employees, and shareholders [5]

Company Overview - Passage Bio, Inc. is a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases [3] - The company's lead product candidate, PBFT02, aims to treat neurodegenerative conditions such as frontotemporal dementia by elevating progranulin levels to restore lysosomal function and slow disease progression [3] Upcoming Events - Management will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City [1] - Will Chou, M.D., president and CEO, will present an overview of the company and engage in one-on-one meetings with investors [2] - A video webcast of the presentation will be available to registered attendees starting September 5, 2025, at 7:00 a.m. ET, and a replay will be accessible for 30 days post-event [2]

CHENGDU, China, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Maase Inc. (NASDAQ: MAAS) (“MAAS” or the “Company”) today announced the successful completion of its strategic acquisition of 100% equity interests in Carve Group Ltd (the “Target Company” or the “Carve Group”). The transaction, previously disclosed in the Company’s Form 6-K filed on July 29, 2025, was formally consummated on August 27, 2025. Pursuant to the transaction agreement dated July 28, 2025, MAAS has acquired all equity interests in the Target Compa ...

CHATHAM, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Tonix’s Chief Executive Officer, will be participating in a fireside chat at the 2025 Cantor Global Healthcare Conference 2025 on Thursday, September 4, 2025 at 1:35 PM ET. A webcast of the fireside chat will be available on the Events ...

研究团队通过自主研发的微创移植技术，成功避免机械通气对供体肺的物理损伤，降低手术创伤。何建行教 授表示，下一步将优化基因编辑策略与抗排异治疗方案，目标将移植器官功能维持时间延长至数月甚至更 久，最终推动异种肺移植进入临床应用阶段。 （图片来源：摄图网） 在全球器官移植需求持续攀升的背景下，异种器官移植技术正从科幻走向现实。 近日，中国研究团队完成世界首例基因编辑猪肺移植至脑死亡人体内的手术，有望为解决全球肺移植供体短 缺问题提供新的思路。相关论文于 8 月 25 日在英国学术期刊《自然-医学》在线发表。 广州医科大学附属第一医院何建行教授团队历时多年攻关，将一个经过6处基因编辑的巴马香猪左肺移植至 脑死亡志愿者体内，完整模拟单肺移植临床场景。术后监测数据显示，移植肺持续维持通气与气体交换功能 达9天，期间未出现超急性排异反应，病原学监测亦未发现感染迹象。 供体猪的6处基因编辑正是基于CRISPR技术完成。科研人员通过敲除导致人类免疫排斥的糖蛋白基因，并插 入人类免疫调节基因，构建出"人源化"猪器官模型。这种策略使异种器官在移植后能有效"伪装"成人体组 织，大幅降低免疫系统攻击风险。 香港大学副教授黄兆麟指出， ...

Agenus (AGEN) Update / Briefing August 27, 2025 04:00 PM ET Company ParticipantsStefanie Perna Nacar - Chief Communications & Government Relations OfficerGaro Armen - Founder, Executive Chairman & CEORichard Goldberg - Chief Development OfficerNicholas DeVito - Assistant ProfessorChristopher O'Callaghan - Senior InvestigatorJennifer Buell - CEO - MiNK Therapeutics & Chair of Executive Committee - AgenusSteven O’Day - Chief Medical OfficerStefanie Perna NacarGood afternoon. My name is Stephanie Nakar and I'm ...